William Blair Reiterates Outperform on Nektar Therapeutics Following NKTR-181 Phase 2 Trial Miss
In a report published Friday, William Blair & Company analyst John Sonnier reiterated an Outperform rating on Nektar Therapeutics (NASDAQ: NKTR).
In the report, William Blair & Company noted, “Although NKTR-181 demonstrated analgesic properties in the Phase II trial, we acknowledge the stock is likely to be weak on Friday because of the near-term uncertainty with the compound. Nektar shares are up 87% in 2013 and closed on Thursday at $13.85. The company has made significant progress with both its proprietary and partnered programs during the year, and we believe it remains a compelling value given the breadth of development with its technology platform, which includes five ongoing Phase III development programs. We believe the shares are likely to be weak today as a result of yesterday's disappointing news; however, NKTR-181 remains a viable asset, in our view.”
Nektar Therapeutics closed on Thursday at $13.85.
Latest Ratings for NKTR
|Nov 2016||Aegis Capital||Initiates Coverage On||Buy|
|Sep 2016||Brean Capital||Assumes||Buy|
|Jan 2016||Janney Capital||Initiates Coverage on||Buy|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.